Project Grant R01HL174965
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$494K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This $560,828 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to define a molecular pathway that regulates the lineage output of multipotent hematopoietic stem and progenitor cells (HSPC) through linker histones. The research conducted under this award from September 2024 to August 2025 will yield novel insights on how lymphoid fate specification is controlled by nucleosome/chromatin...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $242,310 to the University of Washington to investigate the impact of epigenetic heterogeneity on hematopoiesis (blood cell formation). The research project aims to determine the extent of epigenetic state heterogeneity in hematopoietic stem cells and how it may impact their lineage potential. The researchers will utilize a novel...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $107,948 to the Albert Einstein College of Medicine to elucidate the interplay between DDX41 and CUX1 mutations and their impact on hematopoiesis. The research will utilize zebrafish models and human induced pluripotent stem cells (iPSCs) to characterize how these co-occurring mutations in HSPCs drive hematopoietic dysfunction and...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $248,677 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), with a project period from December 1, 2024 to November 30, 2027.
The goal of this research project is to elucidate molecular programs that can be targeted to enhance the function and engraftment of hematopoietic stem cells (HSCs) derived from umbilical...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $503,097 to the Regents of the University of Michigan to study methods for enhancing ex vivo expansion of hematopoietic stem cells (HSCs). The goal is to identify small molecule compounds that can modulate endoplasmic reticulum associated degradation (ERAD) activity to promote HSC maintenance and function during ex vivo culture. This...
This federal Project Grant award of $590,283 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to improve the robustness and reproducibility of human pluripotent stem cell (hPSC) differentiation into cardiomyocytes (CMs) through feedback-controlled closed-loop manufacturing processes. The key goals are to:
Identify 2D CM differentiation failure modes through integrated single-cell transcriptomics and epigenomics...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $792,498 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the Trustees of Indiana University, doing business as Indiana University Indianapolis (IU Indianapolis), with a performance period from December 15, 2024 to November 30, 2028.
The grant supports research to understand the signaling and metabolic changes in hematopoietic stem cells (HSCs) under hypoxic conditions, and explore methods to manipulate these...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,123,357 to Childrens Hospital Medical Center in Cincinnati, Ohio to investigate the microenvironment within bone marrow and its role in regulating blood cell production. The research program has three main objectives: 1) Dissect the specialized microenvironments that function as niches for major blood cell lineages during homeostasis,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI)'s Cardiovascular Diseases Research program (CFDA 93.837) is providing $2,275,731 to the Icahn School of Medicine at Mount Sinai to conduct research on deriving hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs). The goal is to understand the transcriptional and signal requirements for generating this unique population of CD34+ progenitor cells that can home to bone marrow and...
This Project Grant award from the National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) provides $1,630,964 to the University of Southern California (USC) to study the spatial organization and signaling dynamics of hematopoietic stem and progenitor cells (HSPCs) in the bone marrow.
The central objectives are to (1) map the spatial distribution of HSPCs, (2) investigate how their spatial positioning changes during hematopoiesis and in response to specific blood...